BNTC Benitec Net earnings per share (EPS TTM)
Benitec Biopharma Inc. (BNTC) strives for leadership in the treatment of rare dystrophies via its ddRNAi platform. The company's TTM net income per share confirms an investment stage, where the -1.13 parameter determines the metric's magnitude. Asset dynamics depend on clinical trial outcomes rather than macroeconomics, while vector production risks are mitigated by exclusive contracts with contractors.
Metric breakdowns and analytics for Benitec Corp (BNTC)
- stock price and consensus target price:
- market capitalization data:
- business book valuation details:
- debt and liquidity data:
Total Debt to Capital Benitec Biopharma Inc.|BNTC - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Benitec Biopharma Inc|BNTC - Company Cumulative Debt|Debt to Book Capitalization Ratio Benitec Biopharma Inc|BNTC - Long-Term Liabilities|Company Short-Term Debts Benitec Biopharma|Quick Ratio benitec.com
- earnings and valuation multiples indicators:
BNTC - Net Profit|Expected Profit Benitec Biopharma Inc.|BNTC - Company Value to Net Income|Future Price to Earnings Benitec Corp|BNTC - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Benitec Biopharma Inc|BNTC - Operating profit EBITDA|Net earnings per share for the last 12 months Benitec Biopharma|BNTC - Earnings per share for the trailing year|Quarterly EPS earnings growth benitec.com|BNTC - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Benitec Biopharma Inc.
- issuer revenue and sales details:
Basic company analysis:BNTC - Benitec Biopharma Inc.
Portfolio managers evaluate the operating model of Benitec Biopharma Inc. (BNTC) through a rolling annual earnings per share calculation, which objectively measures the business's financial efficiency adjusted for capital dilution. The current value of -1.13 in the 12-month net income per share history reflects the high binary nature of the venture R&D cycle, where the stability of positions depends directly on the success of the clinical validation of gene therapy.
Key competitors
TEM: Net earnings per share for the last 12 months|QGEN (Qiagen Group) - Earnings per share for the last 12 months|Ionis (IONS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Repligen Inc. (RGEN)|RNA (Avidity Biosciences) - Net earnings per share (EPS TTM)|CRSP (CRISPR Therapeutics AG) - Earnings per share for the last four quarters|Earnings per share for the last twelve months GeneDx (WGS)|RARE - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) BEAM (Beam Therapeutics Inc)|Earnings per share for the trailing year SRPT|twistbioscience.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year TXG (10x Genomics, Inc.)|NTLA: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months STOK (Stoke Therapeutics, Inc.)|Net earnings per share for the last 12 months BLFS|Net earnings per one share for the last twelve months Wave Pharma WVE|Net earnings per share for the last 12 months MAZE (Maze Tx)|SION - Net earnings per one share for the last twelve months|Prime Medicine - Net earnings per share for the last 12 months|Taysha Gene Therapies Inc (TSHA) - Net earnings per one share for the last twelve months|uniqure.com - Net earnings per share (EPS TTM)|Net earnings per share for the trailing year MeiraGTx Corp (MGTX)|REGENXBIO (RGNX) - Earnings per share for the last twelve months|SLDB - Net earnings per share for the last four quarters|OCGN (ocugen.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Pacific Biosciences of California, Inc. PACB|Earnings per share for the last twelve months Design Corp (DSGN)|Net earnings per share for the last 12 months Rocket Pharmaceuticals Inc RCKT|FDMT: Net earnings per one share for the last twelve months|LXEO: Earnings per share for the last 12 months|Korro Bio, Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Editas Medicine|Silence Therapeutics (SLN) - Earnings per share for the last twelve months|PRQR (ProQR Therapeutics N.V.) - Earnings per share for the last twelve months|CDXS (Codexis Inc) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months sangamo.com (SGMO)|Net earnings per share (EPS TTM) NAUT|Net earnings per share (EPS TTM) Metagenomi (MGX)|Earnings per share for the last twelve months Precision BioSciences DTIL|Net earnings per share (EPS TTM) Generation Bio Corp GBIO|Boundless Bio, Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Exicure Inc.|Imunon, Inc. (IMNN) - Earnings per share for the last twelve months|RXi Pharmaceuticals (PHIO) - Net earnings per share (EPS TTM)|MBIO (Mustang Bio Corp) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months RNAZ (TransCode Therapeutics)|Net earnings per share (EPS TTM) BNGO|APDN: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) BLUE (bluebird bio Inc.)|Net earnings per share for the last four quarters ImmunoPrecise Antibodies (IPA)|OMGA: Net earnings per share for the last 12 months|OMIC (Singular Genomics Systems Inc) - Earnings per share for the last 12 months|Regulus Therapeutics (RGLS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months syros.com (SYRS)|TBIO (Telesis Bio Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months TRACON Pharmaceuticals Inc. (TCON)|Net earnings per share for the last 12 months UBX (Unity Biotechnology, Inc.)
